They noted that EGFR activity in the tumor tissue of these mice was still decreased after resistance to osimertinib occurred and suggested that progression of BM might not be due to limited drug exposure, but rather due to other molecular factors such as enhanced activity of Ras homolog family member A (RhoA). The gene discussed is RHOA; the disease is neoplasm.